Compare · ELOX vs ZYME
ELOX vs ZYME
Side-by-side comparison of Eloxx Pharmaceuticals Inc. (ELOX) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while ZYME focuses on Biotechnology: Pharmaceutical Preparations.
- ZYME is the larger of the two at $393.4M, about 71.1x ELOX ($5.5M).
- Over the past year, ELOX is up 15.2% and ZYME is up 69.0% - ZYME leads by 53.8 points.
- ZYME has hit the wire 5 times in the past 4 weeks while ELOX has been quiet.
- ZYME has more recent analyst coverage (25 ratings vs 4 for ELOX).
- Company
- Eloxx Pharmaceuticals Inc.
- Zymeworks Inc.
- Price
- $11.81+5.07%
- $24.19-0.10%
- Market cap
- $5.5M
- $393.4M
- 1M return
- -5.82%
- +7.42%
- 1Y return
- +15.22%
- +69.04%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 4
- 25
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Latest ELOX
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
- New insider Domicilium Real Estate Fund Iii Lp claimed ownership of 14,285 shares (SEC Form 3)
- SEC Form 4 filed by Director Kjellson Nina S
- SEC Form 4 filed by Director Webster Stephen W
- SEC Form 4 filed by Director Walts Alan Edmund
- SEC Form 4 filed by Director Rubin Steven D
- SEC Form 4 filed by President and CEO Aggarwal Sumit
- SEC Form 424B4 filed by Eloxx Pharmaceuticals Inc.
- SEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
Latest ZYME
- Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
- EVP & Chief Operating Officer Hollywood Mark was granted 939 shares, increasing direct ownership by 0.71% to 133,852 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Zymeworks to Acquire Theravance Biopharma, Inc.
- Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
- Truist resumed coverage on Zymeworks with a new price target
- SEC Form 4 filed by EVP, General Counsel Schneider Paul R
- New insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)